Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates
- PMID: 18644373
- PMCID: PMC2824882
- DOI: 10.1053/j.gastro.2008.06.038
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates
Abstract
Background & aims: Hepatopulmonary syndrome (HPS) affects 10%-30% of patients with cirrhosis and portal hypertension, but the impact on functional status, quality of life, and survival is poorly defined. We assessed the impact of HPS in patients evaluated for liver transplantation.
Methods: We performed a prospective multicenter cohort study of patients being evaluated for liver transplantation in 7 academic centers in the United States. Patients with HPS (defined as an increased alveolar-arterial oxygen gradient with intrapulmonary vasodilation) were compared with those without HPS in terms of demographics and clinical variables. New York Heart Association functional class, quality of life, and survival were assessed.
Results: Seventy-two patients with HPS and 146 patients without HPS were compared. There were no differences in age, sex, or etiology or severity of liver disease between the groups; however, patients with HPS were less likely to have a history of smoking (P = .03). Patients with HPS had worse New York Heart Association functional class (P = .005) and had significantly worse quality of life in certain domains compared with patients without HPS. In addition, patients with HPS also had a significantly increased risk of death compared with patients without HPS despite adjustment for age, sex, race/ethnicity, Model for End-Stage Liver Disease score, and liver transplantation (adjusted hazard ratio = 2.41; 95% confidence interval, 1.31-4.41; P = .005).
Conclusions: HPS was associated with a significant increase in risk of death as well as worse functional status and quality of life in patients evaluated for liver transplantation.
Conflict of interest statement
The authors have no conflicts of interest to report.
Figures
References
-
- Rodriguez-Roisin R, Krowka MJ, Herve P, et al. on behalf of the ERS Task Force Pulmonary-Hepatic Vascular Disorders Scientific Committee ERS Task Force PHD Scientific Committee. Pulmonary-hepatic vascular disorders (PHD) Eur Respir J. 2004;24:861–880. - PubMed
-
- Arguedas M, Singh H, Faulk D, et al. Utility of pulse oximetry screening for hepatopulmonary syndrome. Clin Gastroenterol Hepatol. 2007;5:749–754. - PubMed
-
- Binay K, Sen S, Biswas PK, et al. Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty. Gastroenterology. 2000;118:192–196. - PubMed
-
- Fuhrmann V, Madl C, Mueller C, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology. 2006;131:69–75. - PubMed
-
- Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. Clin Chest Med. 2005;26:587–597. - PubMed
Publication types
MeSH terms
Grants and funding
- RR00585/RR/NCRR NIH HHS/United States
- M01 RR000585/RR/NCRR NIH HHS/United States
- RR00645/RR/NCRR NIH HHS/United States
- HL67771/HL/NHLBI NIH HHS/United States
- DK064103/DK/NIDDK NIH HHS/United States
- K23 HL067771/HL/NHLBI NIH HHS/United States
- RR00032/RR/NCRR NIH HHS/United States
- RR00046/RR/NCRR NIH HHS/United States
- M01 RR000645/RR/NCRR NIH HHS/United States
- M01 RR000046/RR/NCRR NIH HHS/United States
- DK065958/DK/NIDDK NIH HHS/United States
- R03 DK065958/DK/NIDDK NIH HHS/United States
- M01 RR000032/RR/NCRR NIH HHS/United States
- R03 DK064103/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical